Anti-notch3 antibodies

US12269877B2 · kind B2 · utility

Assignee

• AVEO Pharmaceuticals, Inc. · US

Inventors

• Heidi Okamura · Brookline, US
• Sandra Abbott · Boston, US
• Alisa C. Bell · Bedford, US
• Kelly Kreuter · Arvada, US
• Ronan O'Hagan · Waltham, US
• Samantha Perino · Watertown, US
• Hamid Tissire · Abington, US
• William M. Winston, Jr. · Marlborough, US
• Jeno Gyuris · Lincoln, US

Key dates

• Filing date: Aug 13, 2020
• Grant date: Apr 8, 2025
• Expiry date: Mar 28, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N5/16
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of Notch3.